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Abstract
Prostate cancer can be lethal in advanced stages, for which chemotherapy may become the only
viable therapeutic option. While there is no clear clinical management strategy fitting all patients,
cytotoxic chemotherapy with docetaxel is currently regarded as the gold standard. However, tumors
may regain activity after treatment conclusion and become resistant to docetaxel. This situation
calls for new delivery strategies and drug compounds enabling an improved therapeutic outcome.
Combination of docetaxel with antiangiogenic therapy has been considered a promising strategy.
Bevacizumab is the most common antiangiogenic drug, but clinical studies have not revealed a clear
benefit from its combination with docetaxel. Here, we capitalize on our prior work on mathematical
modeling of prostate cancer growth subjected to combined cytotoxic and antiangiogenic therapies,
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and propose an optimal control framework to robustly compute the drug-independent cytotoxic and
antiangiogenic effects enabling an optimal therapeutic control of tumor dynamics. We describe the
formulation of the optimal control problem, for which we prove the existence of at least a solution
and determine the necessary first order optimality conditions. We then present numerical algorithms
based on isogeometric analysis to run a preliminary simulation study over a single cycle of combined
therapy. Our results suggest that only cytotoxic chemotherapy is required to optimize therapeutic
performance and we show that our framework can produce superior solutions to combined therapy
with docetaxel and bevacizumab. We also illustrate how the optimal drug-na¨ıve cytotoxic effects
computed in these simulations may be successfully leveraged to guide drug production and delivery
strategies by running a nonlinear least-square fit of protocols involving docetaxel and a new design
drug. In the future, we believe that our optimal control framework may contribute to accelerate
experimental research on chemotherapeutic drugs for advanced PCa and ultimately provide a means
to design and monitor its optimal delivery to patients.
Keywords: prostate cancer; chemotherapy; computational oncology; phase field; semilinear parabolic
equations; isogeometric analysis; optimal control
AMS Subject Classification: 35Q92, 35Q93, 92C50, 65M60, 35K51, 35K58, 49J20, 49K20
1 Introduction
Prostate cancer (PCa) is the second most common cancer among men worldwide [21]. Current
estimates indicate that the annual number of new cases globally exceeds 1,000,000. PCa is also
responsible for over 300,000 worldwide deaths yearly and a major economic burden for our health
care systems.
In most cases, PCa is an adenocarcinoma — a form of cancer that originates and develops in
epithelial tissues. PCa is easier to treat in its early stages, especially before it spreads out of the
prostate [96]. Although the disease rarely produces any symptoms before the tumor has advanced
significantly, current screening protocols have helped identify PCa patients early [68, 96]. The most
common screening method for PCa is the Prostate Specific Antigen (PSA) test — a blood test that
measures the serum level of gamma-seminoprotein which is a biomarker of the prostate activity. PSA-
based screening is controversial in the urology community, primarily because it is prostate-specific,
but not cancer-specific [96]. Despite the success of screening protocols, a significant number of
patients eventually develops advanced PCa [9, 96]. These include men who are diagnosed late, and
patients who initially receive radical treatment (e.g., surgery or radiation) or follow a conservative
management protocol (e.g., active surveillance), but experience cancer progression.
The most common treatments for advanced PCa are hormonal therapy and chemotherapy, but
the latter may become the only remaining alternative after PCa becomes insensitive to hormonal
strategies [68, 96]. Here, we will focus on chemotherapy, which normally relies on cytotoxic drugs.
These compounds aim at interrupting cell division and promoting cell death, hence contributing to
reduce tumor progression. Cytotoxic chemotherapy for advanced PCa usually relies on the periodic
delivery of docetaxel every three weeks [19, 68, 68, 83, 96]. However, treated tumors may resume
growth months after the conclusion of therapy and develop resistance to docetaxel, hence requiring
the use of alternative cytotoxic drugs for a second round of treatment. Angiogenesis has also been
regarded as a promising therapeutic target for advanced PCa because it is known to play a pivotal role
in the progression of advanced PCa and higher microvascular density correlates with poorer prognosis
[65, 70, 95]. Antiangiogenic drugs block the formation of new blood vessels cutting off the supply of
critical nutrients to the tumor. Bevacizumab is an extensively studied antiangiogenic drug that has
also being investigated for the treatment of advanced PCa either as monotherapy or in combination
with cytotoxic chemotherapy [2, 71, 83, 85]. A clinical study showed that castration-resistant PCa
patients did not benefit from treatment with bevacizumab alone [78], but another study showed
2
that 75% of the patients treated with bevacizumab experienced a 50% PSA decline when taking
bevacizumab in combination with cytotoxic chemotherapy [76]. However, multiple experimental and
clinical studies have shown contradictory evidence about the effectiveness of antiangiogenic therapy
for advanced PCa either as monotherapy or combined with a cytotoxic agent [2, 48, 71, 74, 83, 85–
87, 89].
Thus, developing optimal dosing strategies for chemotherapeutic drugs is an open problem of
major medical interest, but it is particularly difficult when two or more drugs are combined because
their joint effect may produce unexpected outcomes and toxicities. Recently, the use of mathematical
models to describe the growth and treatment of cancer has been increasing our understanding of
these pathologies and providing a means to monitor and forecast tumor growth via patient-specific
computer simulations, which can assist physicians in clinical decision-making [1, 5, 10, 18, 72, 79,
100, 101]. Several studies have focused on the effects of chemotherapeutic strategies for various
types of tumors [8, 24, 34, 39, 46, 50, 77, 101]. In this context, optimal control theory provides
a robust framework to obtain optimal drug protocols according to a given mathematical model of
tumor growth and treatment [6, 12, 15, 17, 25, 45, 52, 53, 73, 94]. We argue that these quantitative
approaches can play a significant role in the design of optimal drug regimens, providing the best
dosing, timing, and even drug pharmacodynamics to treat each patient’s tumor [39, 45, 63, 101].
Hence, optimal drug protocols can help us reduce the total amount of drug needed to achieve a
target tumor size reduction, which is very important considering the harsh side effects of cytotoxic
and antiangiogenic drugs [2, 19, 68, 71, 83, 83, 85]. Because antiangiogenic and cytotoxic drugs
attack the tumor using different mechanisms, mathematical modeling can also help us determine
the most effective drug dose combination. Additionally, optimal pharmacodynamics derived from
optimal control problems could ultimately be exploited to guide the design of new drug compounds
[38, 40, 63, 84].
Here, we propose an optimal control framework that relies on a recently proposed model of PCa
growth accounting for the effect of cytotoxic and antiangiogenic drugs [16]. Our approach aims at
finding the cytotoxic and antiangiogenic drug effects minimizing an array of common quantities of
interest in clinical and experimental settings, such as tumor volume and serum PSA. We demonstrate
the existence of unique solutions and derive the optimality conditions for our optimal control problem.
Then, we propose a set of numerical algorithms to solve this optimal control problem and we use them
to run a simulation study. Our computational methods rely on isogeometric analysis (IGA), a recent
generalization of the finite element method with superior approximation properties granted by the use
of splines as basis functions [37]. Our simulation study results in optimal therapeutic solutions that
only feature cytotoxic effects, and hence suggests that antiangiogenic therapies may not be optimal for
treating PCa. Because docetaxel and bevacizumab are reference drugs in therapeutic investigations
of advanced PCa, we used their properties to build the initial guesses and admissible space of controls.
However, our optimal control problem is drug-independent, i.e., it provides optimal cytotoxic and
antiangiogenic drug effects without accounting for any specific drug delivery plan. Thus, in this
work, we also capitalize on this advantageous property and propose a two-stage methodology to
derive optimal drug compounds and delivery plans matching the optimal drug effects targeting a
specific tumor: first, we calculate the optimal drug-na¨ıve optimal effects via computer simulation of
our optimal control problem, and, second, we run nonlinear least-square fits of an array of elective
drug delivery plans and compounds. Our results show that our approach can render interesting
optimal drug protocols matching the optimal drug effects to treat the target tumor.
The paper is organized as follows. Section 2 briefly describes our mathematical model for PCa
growth featuring cytotoxic and antiangiogenic drug effects, as well as the formulation of the optimal
control problem. Sections 3 and 4 present the existence results and the optimality conditions for
the optimal control problem, respectively. Section 5 introduces the numerical algorithms that we
propose in order to solve it, and we use these computational methods in a simulation study presented
in Section 6. Then, we use the resulting optimal drug effects to illustrate how they can guide drug
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design and the conception of new drug delivery strategies in Section 7. Finally, in Section 8 we
discuss the work presented herein, draw conclusions, and address future avenues of research.
2 Mathematical model
2.1 Prostate cancer model with cytotoxic and antiangiogenic therapies
We leverage a recently proposed mathematical model of PCa growth [16] that includes the effect of
cytotoxic and antiangiogenic drugs. Reference [16] includes a detailed description of the biological
mechanisms considered in the model, and a biological interpretation of its parameters. Let Ω ⊂ Rd
be an open bounded set and d the number of spatial dimensions. Let φ0, σ0, and p0 be sufficiently
smooth given functions defined in Ω. The set Ω has a sufficiently smooth boundary ∂Ω and T is a
finite time. By defining the space/time sets QT := (0, T ) × Ω and ΣT := (0, T ) × ∂Ω, the model
can be formulated as
φt − λ∆φ+ F ′(φ)−m(σ)h′(φ) = −Uh′(φ) in QT , (2.1)
σt − η∆σ + γhσ + γchσφ = Sh(1− φ) + (Sc − S)φ in QT , (2.2)
pt −D∆p+ γpp = αh + αchφ in QT , (2.3)
φ = 0,
∂σ
∂ν
=
∂p
∂ν
= 0 in ΣT , (2.4)
φ(0, x) = φ0(x), σ(0, x) = σ0(x), p(0, x) = p0(x) in Ω, (2.5)
where φ is a phase-field that identifies the spatial location of the tumor; σ is the concentration of a
vital nutrient; and p is the tissue PSA concentration. The serum PSA Ps commonly used in clinical
practice can be obtained as Ps =
∫
Ω p dx [16, 61]. The differential operators in the equations are
defined as follows: the subscript t indicates partial differentiation with respect to time; ∆ denotes the
Laplace operator with respect to the space variables; F ′ denotes the derivative of F and ∂∂ν represents
the outward normal derivative to ∂Ω. In Eq. (2.1), F (φ) = Mφ2(1−φ)2 and h(φ) = Mφ2(3− 2φ),
where M is a positive constant. We will also use the notation
γch := γc − γh, αch := αc − αh, Sch := Sc − Sh. (2.6)
The model parameters λ, η, D, γp, γc, γh, αc, αh, Sc and Sh are positive constants with biological
significance; see Ref. [16]. For the solution of the initial boundary value problem (2.1)–(2.5), the
functions U(t, x) and S(t, x) are considered to be given. U(t, x) models the inhibiting effect of a
cytotoxic drug on tumor dynamics, while S(t, x) represents the reduction of nutrient supply produced
by an antiangiogenic drug. The function m(σ) is defined as
m(σ) = mref
(
ρ+A
2
+
ρ−A
pi
arctan
(
σ − σl
σr
))
(2.7)
where mref is a positive constant, while ρ and A are constants that determine the rate of cell
proliferation and apoptosis. We define ρ = Kρ/Kρ and A = −KA/KA. Here, Kρ and KA are,
respectively, the proliferation and apoptosis rates of tumor cells while Kρ and KA are scaling positive
constants. The positive constants σl and σr are, respectively, a reference and a threshold value for
the nutrient concentration; see Ref. [16].
2.2 Optimal control problem
Our optimal control problem consists in finding the functions U(t, x) and S(t, x) that provide the
optimal cytotoxic and antiangiogenic effects to treat a certain PCa case. Therefore, our optimal
control problem can be stated as
Minimize {J(U, S); (U, S) ∈ Uad}, (P )
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subject to Eq. (2.1)–(2.5), where
J(U, S) =
k1
2
∫
QT
(φ(t, x)− φQ)2dxdt+ k2
2
∫
Ω
(φ(T, x)− φΩ)2dx+ k3
∫
Ω
φ(T, x)dx
+
k4
2
∫ T
0
[(∫
Ω
p(t, x)dx− pΩ(t)
)+]2
dt+ k5
∫
Ω
p(T, x)dx
+
k6
2
∫
QT
U2(t, x)dxdt+
k7
2
∫
QT
S2(t, x)dxdt (2.8)
and
Uad = {(U, S) ∈ L∞(QT )× L∞(QT ); 0 ≤ U ≤ Umax, 0 ≤ S ≤ Smax, a.e. in QT }. (2.9)
The quantities Umax and Smax are two threshold positive values such that Smax ≤ Sc. In
Eq. (2.8), r+ represents the positive part of r; the functions φQ, φΩ are prescribed targets for the
tumor phase field in QT and in Ω at the final time, respectively, while pΩ represents an upper target
function for the spatial mean value of the tissue PSA (i.e., an upper target for the serum PSA). We
assume that
φQ ∈ L2(QT ), φΩ ∈ L2(Ω), pΩ ∈ L2(0, T ). (2.10)
Notice that we have not imposed any specific drug delivery plan or pharmacodynamic properties
for U(t, x) and S(t, x) in our mathematical model and the optimal control problem herein, hence
making our approach drug-independent and solely relying on the type of therapy itself. In this context,
Uad aims at defining feasible limits for the therapeutic effects that can be realistically achieved with
common drugs. The optimal choice of delivery dates, doses and even pharmacodynamic properties
can be made at a second stage, aiming at reproducing the optimal drug-na¨ıve effects obtained from
the optimal control problem described in this section (see Section 7).
The coefficients ki, i = 1, ..., 7, in Eq. (2.8) are nonnegative constants, such that there exists
at least one i with ki > 0. In the numerical simulations presented in Section 6, we will focus on
particular examples of the functional J , where only a few of the ki’s are simultaneously nonzero.
For example, the first three terms in J , weighted by k1, k2, and k3, respectively, provide a slightly
different control of the tumor extent. In our numerical simulations, not all three constants k1, k2,
and k3 will be nonzero simultaneously. The same argument can be applied to the constants k4
and k5, which provide control of the PSA. The terms weighted by k6 and k7 control the relative
participation of cytotoxic and antiangiogenic effects, which may ultimately control the total amount
of drugs delivered (see Ref. [16] and Sections 6–7). The control of the total amount of drug may be
especially important because some therapeutic compounds have very strong side effects. However,
specific dose-dependent toxicities can be accounted for during the design of optimal drug protocols
aiming at reproducing the optimal drug-na¨ıve effects obtained from our optimal control problem (see
Sections 6, 7, and 8).
3 Existence results
The functional framework involves the space H = L2(Ω), which is identified with its dual space
H ′ ≡ H, and the Sobolev spaces H1(Ω) and H10 (Ω), the last one containing the elements of H1(Ω)
with null trace on the boundary ∂Ω. We set
V0 = H
1
0 (Ω), V
′
0 = (H
1
0 (Ω))
′ =: H−1(Ω), V = H1(Ω), V ′ = (H1(Ω))′,
as well as
W0 = H
2(Ω) ∩H10 (Ω), W =
{
y ∈ H2(Ω); ∂y
∂ν
= 0 on ∂Ω
}
,
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with the dense and compact injections W0 ⊂ V0 ⊂ H ⊂ V ′0 and W ⊂ V ⊂ H ⊂ V ′. For the norms
in these spaces we will use the notation ‖ · ‖B, where B is the space we are considering.
For r ∈ [1,∞] and z ∈ Lr(Ω) or z ∈ Lr(QT ) we simply denote the norms of z by ‖z‖r .
We will also make use of spaces of functions that depend on time with values in a Banach space
B. Namely, for r ∈ [1,∞] we consider the space Lr(0, T ;B) of measurable functions t 7→ z(t) such
that t 7→ ‖z(t)‖rB is integrable on (0, T ) (or essentially bounded if r =∞) and the space C([0, T ];B)
of continuous functions from [0, T ] to B. Perhaps, it is important to note that L2(0, T ;H) is a space
completely isomorphic to L2(QT ). Moreover, for r ∈ [1,∞], W 1,r(0, T ;B) will denote the space of
functions t 7→ z(t) such that both z and its (weak) derivative zt belong to Lr(0, T ;B). We point
out that W 1,r(0, T ;B) ⊂ C([0, T ];B) for all r ∈ [1,∞].
Hypotheses. According to the explanation already given, we emphasize that
F ∈ C∞(R), h ∈ C∞(R), m ∈ C∞(R), (3.1)
m, m′ are Lipschitz continuous on R, (3.2)
m, m′, m′′ ∈ L∞(R). (3.3)
Let us introduce the spaces
X0 = W
1,2(0, T ;V ′0) ∩ C([0, T ];H) ∩ L2(0, T ;V0),
X = W 1,2(0, T ;V ′) ∩ C([0, T ];H) ∩ L2(0, T ;V ), (3.4)
X0 = W 1,2(0, T ;H) ∩ C([0, T ];V0) ∩ L2(0, T ;W0),
X = W 1,2(0, T ;H) ∩ C([0, T ];V ) ∩ L2(0, T ;W ). (3.5)
Definition 3.1. A solution to system (2.1)-(2.5) is a triplet (φ, σ, p), with φ ∈ X0 ∩ L∞(QT ),
σ ∈ X, p ∈ X, which satisfies∫ T
0
〈φt(t), ψ(t)〉V ′0 ,V0 dt+
∫
QT
{
λ∇φ · ∇ψ + (F ′(φ)−m(σ)h′(φ))ψ} dxdt
= −
∫
QT
Uh′(φ)ψdxdt, for all ψ ∈ (0, T ;V0), (3.6)
∫ T
0
〈σt(t), ψ(t)〉V ′,V dt+
∫
QT
(η∇σ · ∇ψ + (γhσψ + γchσφψ)dxdt
=
∫
QT
(Sh + (Sch − S)φ)ψdxdt, for all ψ ∈ L2(0, T ;V ), (3.7)
∫ T
0
〈pt(t), ψ(t)〉V ′,V dt+
∫
QT
(D∇p · ∇ψ + γppψ)dxdt
=
∫
QT
(αh + αchφ)ψdxdt, for all ψ ∈ L2(0, T ;V ), (3.8)
and
(ϕ, σ, p)(0) = (ϕ0, σ0, p0) a.e. in Ω. (3.9)
Theorem 3.2. Let (U, S) ∈ Uad,
(φ0, σ0, p0) ∈ H ×H ×H, (3.10)
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0 ≤ φ0(x) ≤ 1 a.e. x ∈ Ω. (3.11)
Then, system (2.1)-(2.5) has a unique solution (φ, σ, p), with
0 ≤ φ(t, x) ≤ 1 a.e. (t, x) ∈ QT , (3.12)
which satisfies the estimate
‖φ‖2X0 + ‖σ‖2X + ‖p‖2X
≤ C(‖φ0‖2H + ‖σ0‖2H + ‖p0‖2H + ‖U‖2L2(0,T ;H) + ‖S‖2L2(0,T ;H) + 1). (3.13)
If
(σ0, p0) ∈ L∞(Ω)× L∞(Ω), σ0(x) ≥ 0, p0(x) ≥ 0 a.e. x ∈ Ω, (3.14)
then we have (σ, p) ∈ L∞(QT )× L∞(QT ),
σ(t, x) ≥ 0, p(t, x) ≥ 0 a.e. (t, x) ∈ QT , (3.15)
and (σ, p) fulfills the estimate
‖σ‖∞ ≤ C(‖σ0‖∞ + 1), ‖p‖∞ ≤ C(‖p0‖∞ + 1). (3.16)
Moreover, the solution is continuous with respect to the data, that is, for two solutions (φi, σi, pi)
corresponding to (φi0, σ
i
0, p
i
0, Ui, Si), i = 1, 2, we have
‖(φ1 − φ2)(t)‖2H + ‖(σ1 − σ2)(t)‖2H + ‖(p1 − p2)(t)‖2H
+ ‖φ1 − φ2‖2L2(0,T ;V0) + ‖σ1 − σ2‖2L2(0,T ;V ) + ‖p1 − p2‖2L2(0,T ;V )
≤ C
(∥∥φ10 − φ20∥∥2H + ∥∥σ10 − σ20∥∥2H + ∥∥p10 − p20∥∥2H
+ ‖U1 − U2‖2L2(0,T ;H) + ‖S1 − S2‖2L2(0,T ;H)
)
(3.17)
for all t ∈ [0, T ]. Finally, if (φ0, σ0, p0) ∈ V0 × V × V, the solution has the supplementary regularity
(φ, σ, p) ∈ X0 ×X × X , and satisfies the estimate
‖φ‖2X0 + ‖σ‖2X + ‖p‖2X
≤ C(‖φ0‖2V0 + ‖σ0‖2V + ‖p0‖2V + ‖U‖2L2(0,T ;H) + ‖S‖2L2(0,T ;H) + 1). (3.18)
The proof of this result can be found in Ref. [16].
Theorem 3.3. Assume (3.11), (3.14), and (2.10). Then, there exists at least one solution
(U∗, S∗) ∈ Uad to problem (P ), with the corresponding optimal state (φ∗, σ∗, p∗) solving (2.1)-
(2.5) in the sense of Definition 3.1.
Proof. It is easy to check that the functional J is nonnegative, so that it has an infimum d ≥ 0.
We consider a minimizing sequence (Un, Sn) ∈ Uad such that
d ≤ J(Un, Sn) ≤ d+ 1
n
, for n ≥ 1. (3.19)
The state system corresponding to (Un, Sn) has, according to Theorem 3.2, a unique solution
(φn, σn, pn) satisfying the estimates (3.12), (3.13), and (3.16). Selecting a subsequence, still denoted
by n, we can write
Un → U∗, Sn → S∗ weak-star in L∞(QT ),
φn → φ∗ weakly in W 1,2(0, T ;V ′0) ∩ L2(0, T ;V0), weak-star in L∞(QT ),
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σn → σ∗ weakly in W 1,2(0, T ;V ′) ∩ L2(0, T ;V ), weak-star in L∞(QT ),
pn → p∗ weakly in W 1,2(0, T ;V ′) ∩ L2(0, T ;V ), weak-star in L∞(QT ).
Applying Lions’ compactness theorem (see Ref. [58], p. 58) we deduce that
φn → φ∗, σn → σ∗, pn → p∗ strongly in L2(0, T ;H). (3.20)
By Ascoli-Arzela` theorem we also obtain that
φn(t)→ φ∗(t) strongly in V ′0 , uniformly in t ∈ [0, T ], (3.21)
σn(t)→ σ∗(t) strongly in V ′, uniformly in t ∈ [0, T ], (3.22)
pn(t)→ p∗(t) strongly in V ′, uniformly in t ∈ [0, T ], (3.23)
whence φ∗(0) = φ0, σ∗(0) = σ0, p∗(0) = p0. In addition, φ∗, σ∗, p∗ ∈ L∞(QT ) and satisfy (3.12),
(3.15), and (3.16).
Using the boundedness and the Lipschitz continuity of F ′ and h′ in the interval [0, 1], we derive
that
F ′(φn)→ F ′(φ∗), h′(φn)→ h′(φ∗) strongly in L2(QT ), weak-star in L∞(QT ).
By (3.2) and (3.3) we obtain
m(σn)→ m(σ∗) strongly in L2(QT ), weak-star in L∞(QT ),
whence
m(σn)h
′(φn)→ m(σ∗)h′(φ∗) strongly in L2(QT ),
φnσn → φ∗σ∗ strongly in L2(QT ),
and
Unh
′(φn)→ U∗h′(φ∗) weakly in L2(QT ),
Snφn → S∗φ∗ weakly in L2(QT ).
Then, we can pass to the limit in the variational formulations (3.6)-(3.8) for the solution (φn, σn, pn)
and deduce that (φ∗, σ∗, p∗) is the solution to (2.1)-(2.5) corresponding to (U∗, S∗).
From (3.13) we see that φn(T ), pn(T ) are uniformly bounded in H, so that φn(T ) → φ∗(T )
and pn(T )→ p∗(T ) weakly in H by (3.21) and (3.23), and consequently
k3
∫
Ω
φn(T )dx→ k3
∫
Ω
φ∗(T )dx, k5
∫
Ω
pn(T )dx→ k5
∫
Ω
p∗(T )dx. (3.24)
Also, with the help of (3.20) and the Lipschitz continuity of the positive part, it turns out that(∫
Ω
pn(·)dx− pΩ(·)
)+
→
(∫
Ω
p∗(·)dx− pΩ(·)
)+
strongly in L2(0, T ). (3.25)
We aim at showing that J(U∗, S∗) ≤ lim inf
n→∞ J(Un, Sn) = limn→∞ J(Un, Sn) = d by (3.19), whence
J(U∗, S∗) = d and so (U∗, S∗) is an optimal control in (P ). Indeed, the second and the last two
terms in J(Un, Sn) are weakly lower semicontinuous and
k2
2
∫
Ω
(φ∗(T )− φΩ)2dx+ k6
2
∫
QT
(U∗)2dxdt+
k7
2
∫
QT
(S∗)2dxdt
≤ lim inf
n→∞
(
k2
2
∫
Ω
(φn(T )− φΩ)2dx+ k6
2
∫
QT
U2ndxdt+
k7
2
∫
QT
S2ndxdt
)
.
On the other hand, we point out that the other four therms in J(Un, Sn) converge, as previously
specified. This concludes the proof. 
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4 Optimality conditions
Let (U∗, S∗) ∈ Uad be an optimal control in (P ) with the corresponding state (φ∗, σ∗, p∗) and let
(u, s) ∈ L2(0, T ;H)× L2(0, T ;H). We introduce the linearized system
Yt − λ∆Y + (F ′′(φ∗)−m(σ∗)h′′(φ∗) + U∗h′′(φ∗))Y −m′(σ∗)h′(φ∗)Z
= − uh′(φ∗), in QT , (4.1)
Zt − η∆Z + (γh + γchφ∗)Z + (γchσ∗ + S∗ − Sch)Y = −sφ∗ in QT , (4.2)
Pt −D∆P + γpP − αchY = 0, in QT , (4.3)
Y = 0,
∂Z
∂ν
=
∂P
∂ν
= 0, on ΣT , (4.4)
Y (0) = 0, Z(0) = 0, P (0) = 0, in Ω. (4.5)
Proposition 4.1. The system (4.1)-(4.5) has a unique strong solution (Y,Z, P ) ∈ X0 × X × X ,
satisfying
‖Y ‖2X0 + ‖Z‖2X + ‖P‖2X ≤ C(‖u‖2L2(0,T ;H) + ‖s‖2L2(0,T ;H)), (4.6)
where the spaces X0 and X are defined in (3.5).
Proof. We note that equations (4.1)-(4.3) are linear parabolic and have the coefficients of Y, Z
and P in L∞(QT ) and the source terms in L2(0, T ;H), according to (3.1)-(3.3) and to the property
0 ≤ φ∗ ≤ 1 a.e. in QT . The initial data are zero, then smooth. Therefore, by the general results
concerning the existence and uniqueness of the solutions to linear parabolic systems (cf. Ref. [57]),
we deduce that there is a unique triplet (Y,Z, P ) ∈ X0 × X × X solving (4.1)-(4.3) and satisfying
estimate (4.6). 
Next, let (U∗, S∗) ∈ Uad be an optimal control in (P ) with the corresponding state (φ∗, σ∗, p∗).
Let µ ∈ (0, 1) and define
Uµ = U∗ + µu, Sµ = S∗ + µs, (4.7)
where
(u, s) = (u¯− U∗, s¯− S∗), for some (u¯, s¯) ∈ Uad. (4.8)
We set
Y µ =
φµ − φ∗
µ
− Y, Zµ = σ
µ − σ∗
µ
− Z, Pµ = p
µ − p∗
µ
− P, (4.9)
where (φµ, σµ, pµ) is the solution to (3.6)-(3.9) corresponding to (Uµ, Sµ) ∈ Uad and (Y,Z, P )
solves (4.1)-(4.5) with (u, s) defined by (4.8).
Theorem 4.2. The following convergence properties hold
Y µ → 0 strongly in C([0, T ];H) ∩ L2(0, T ;V0),
Zµ → 0 strongly in C([0, T ];H) ∩ L2(0, T ;V ),
Pµ → 0 strongly in C([0, T ];H) ∩ L2(0, T ;V )
and so they show that (4.1)-(4.5) is precisely the system of first order variations related to (2.1)-(2.5).
Proof. We write the system satisfied by (Y µ, Zµ, Pµ) :
Y µt − λ∆Y µ + a1Y µ + a2Y + a3Zµ + a4Z = −u(h′(φµ)− h′(φ∗)), in QT , (4.10)
Zµt − η∆Zµ + b1Y µ + b2Y + b3Zµ = −s(φµ − φ∗), in QT , (4.11)
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Pµt −D∆Pµ + γpPµ − αchY µ = 0, in QT , (4.12)
Y µ = 0,
∂Zµ
∂ν
=
∂Pµ
∂ν
= 0, on ΣT , (4.13)
Y µ(0) = 0, Zµ(0) = 0, Pµ(0) = 0, in Ω, (4.14)
where
a1 := F
′′(φµint)− h′′(φint,µ)(m(σ∗)− U∗), (4.15)
a2 := F
′′(φµint)− F ′′(φ∗)− (h′′(φint,µ)− h′′(φ∗))(m(σ∗)− U∗), (4.16)
a3 := −m′(σµint)h′(φµ), (4.17)
a4 := m
′(σ∗)h′(φ∗)−m′(σµint)h′(φµ), (4.18)
b1 := γchσ
µ + S∗ − Sch, b2 := γch(σµ − σ∗), b3 := γh + γchφ∗. (4.19)
Here, φµint, σ
µ
int and φint,µ are measurable functions (see Appendix A) occurring in the Taylor ex-
pansions of F ′(φµ), m(σµ), h′(φµ), indeed, having the form
φµint = θµφ
∗ + (1− θµ)φµ, for some function θµ taking values in (0, 1),
with similar expressions for σµint and φint,µ. Since U
µ → U∗ and Sµ → S∗ strongly in L2(QT ) as
µ→ 0, then by estimate (3.17) we see that
φµ → φ∗, σµ → σ∗, pµ → p∗ strongly in C([0, T ];H), (4.20)
whence
φµint → φ∗, σµint → σ∗, φint,µ → φ∗ strongly in C([0, T ];H). (4.21)
We test (4.10) by Y µ, (4.11) by Zµ, (4.12) by Pµ and sum up all of them, obtaining
1
2
‖Y µ(t)‖2H + λ
∫ t
0
‖∇Y µ(τ)‖2H dτ +
1
2
‖Zµ(t)‖2H + η
∫ t
0
‖∇Zµ(τ)‖2H dτ
+
1
2
‖Pµ(t)‖2H +D
∫ t
0
‖∇Pµ(τ)‖2H dτ + γp
∫ t
0
‖Pµ(τ)‖2H dτ
≤
∫
Qt
|a1||Y µ|2dxdτ +
∫
Qt
|a2||Y ||Y µ|dxdτ +
∫
Qt
|a3||Zµ||Y µ|dxdτ
+
∫
Qt
|a4||Z||Y µ|dxdτ +
∫
Qt
|b1||Y µ||Zµ|dxdτ +
∫
Qt
|b2||Y ||Zµ|dxdτ
+
∫
Qt
|b3||Zµ|2dxdτ +
∫
Qt
|αch||Y µ||Pµ|dxdτ
+
∫
Qt
|u||h′(φµ)− h′(φ∗)||Y µ|dxdτ +
∫
Qt
|s||φµ − φ∗||Zµ|dxdτ. (4.22)
We see that a1, a3, b1, b3 are uniformly bounded in L
∞(QT ) and, by (4.8), we have that |u| ≤ Umax,
|s| ≤ Smax a.e in QT . Then, by the Young inequality, it follows that∫
Qt
|a1||Y µ|2dxdτ +
∫
Qt
|a3||Zµ||Y µ|dxdτ +
∫
Qt
|b1||Y µ||Zµ|dxdτ
+
∫
Qt
|b3||Zµ|2dxdτ +
∫
Qt
|αch||Y µ||Pµ|dxdτ
≤ C
(∫
Qt
|Y µ|2dxdτ +
∫
Qt
|Zµ|2dxdτ +
∫
Qt
|Pµ|2dxdτ
)
.
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Next, by applying the Ho¨lder inequality and the continuous embedding V0 ⊂ L4(Ω), we easily infer
that ∫
Qt
|a2||Y ||Y µ|dxdτ ≤
∫ t
0
‖a2(τ)‖H ‖Y (τ)‖4 ‖Y µ(τ)‖4 dτ
≤ C
∫ t
0
‖a2(τ)‖H ‖Y (τ)‖V0 ‖Y µ(τ)‖V0 dτ
≤ λ
4
∫ t
0
‖∇Y µ(τ)‖2H dτ + C ‖Y ‖2L∞(0,T ;V0)
∫ t
0
‖a2(τ)‖2H dτ
≤ λ
4
∫ t
0
‖∇Y µ(τ)‖2H dτ + C
∫ t
0
‖a2(τ)‖2H dτ,
where we used (4.6). The following remaining terms on the right-hand side of (4.22) can be treated
in the same way, in order to find out that∫
Qt
|a4||Z||Y µ|dxdτ +
∫
Qt
|b2||Y ||Zµ|dxdτ
≤ λ
4
∫ t
0
‖∇Y µ(τ)‖2H dτ + C
∫ t
0
‖a4(τ)‖2H dτ +
η
2
∫ t
0
‖∇Zµ(τ)‖2H dτ
+
η
2
∫ t
0
‖Zµ(τ)‖2H dτ + C
∫ t
0
‖b2(τ)‖2H dτ.
Going back to (4.22), we obtain
1
2
‖Y µ(t)‖2H +
λ
2
∫ t
0
‖∇Y µ(τ)‖2H dτ +
1
2
‖Zµ(t)‖2H +
η
2
∫ t
0
‖∇Zµ(τ)‖2H dτ
+
1
2
‖Pµ(t)‖2H +D
∫ t
0
‖∇Pµ(τ)‖2H dτ + γp
∫ t
0
‖Pµ(τ)‖2H dτ
≤ C
(∫ t
0
‖Y µ(τ)‖2H dτ +
∫ t
0
‖Zµ(τ)‖2H dτ +
∫ t
0
‖Pµ(τ)‖2H dτ
)
+ C
(∫ t
0
‖a2(τ)‖2H dτ +
∫ t
0
‖a4(τ)‖2H dτ +
∫ t
0
‖b2(τ)‖2H dτ
)
+ C
∫ t
0
‖(φµ − φ∗)(τ)‖2H dτ, (4.23)
by using the Lipschitz continuity of the function h′. An application of the Gronwall lemma leads to
‖Y µ(t)‖2H +
∫ t
0
‖∇Y µ(τ)‖2H dτ + ‖Zµ(t)‖2H +
∫ t
0
‖∇Zµ(τ)‖2H dτ
+ ‖Pµ(t)‖2H +
∫ t
0
‖Pµ(τ)‖2V dτ
≤ C
(
‖a2‖2L2(QT ) + ‖a4‖
2
L2(QT )
+ ‖b2‖2L2(QT )
+ ‖φµ − φ∗‖2L2(QT )
)
, for all t ∈ [0, T ]. (4.24)
Recalling (4.20), (4.21) and the boundedness and Lipschitz continuity of F ′′, h′, h′′ in [0, 1] and of
m′ in R, it is not difficult to check that a2, a4, b2 and the last term in (4.24) tend to zero strongly
in L2(QT ), as µ→ 0. Thanks to (4.24) this implies that
Y µ → 0, Zµ → 0, Pµ → 0 strongly in C([0, T ];H) ∩ L2(0, T ;V ).
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Therefore, we see that
lim
µ→0
φµ − φ∗
µ
= Y, lim
µ→0
σµ − σ∗
µ
= Z, lim
µ→0
pµ − p∗
µ
= P,
where the limit is understood in the sense of the strong convergence in C([0, T ];H) ∩ L2(0, T ;V ).
This concludes the proof. 
At this point, we can introduce the adjoint system in terms of the adjoint variables w, z, q :
− wt − λ∆w + (F ′′(φ∗)−m(σ∗)h′′(φ∗) + U∗h′′(φ∗))w
+ (γchσ
∗ + (S∗ − Sch))z − αchq = k1(φ∗ − φQ), in QT , (4.25)
− zt − η∆z + (γh + γchφ∗)z −m′(σ∗)h′(φ∗)w = 0, in QT , (4.26)
− qt −D∆q + γpq = k4
(∫
Ω
p∗(·)dx− pΩ(·)
)+
, in QT , (4.27)
w = 0,
∂z
∂ν
=
∂q
∂ν
= 0, on ΣT , (4.28)
w(T ) = k2(φ
∗(T )− φΩ) + k3, z(T ) = 0, q(T ) = k5, in Ω, (4.29)
where ki, i = 1, ..., 5, and φQ, φΩ, pΩ are the coefficients and the functions involved in the cost
functional (2.8).
Proposition 4.3. The system (4.25)-(4.29) has a unique variational solution (w, z, q) ∈ X0×X×X,
satisfying
‖w‖X0 + ‖z‖X + ‖q‖X ≤ C, (4.30)
where C is a constant depending on the norms ‖F ′′‖L∞([0,1]) , ‖m‖L∞(R) , ‖h′′‖L∞([0,1]) , ‖σ∗‖∞ ,
‖φ∗(T )− φΩ‖L2(Ω) , ‖φ∗ − φQ‖L2(QT ) , ‖m′‖L∞(R) , ‖h′‖L∞([0,1]) ,
∥∥∥(∫Ω p∗(·)dx− pΩ(·))+∥∥∥L2(0,T ),
Umax, Smax, Ω, T, the problem parameters and all ki, i = 1, ..., 5.
Proof. Using the transformation t 7→ T −t, we can rewrite (4.25)-(4.29) as a linear parabolic system
with initial conditions in H and with the coefficients of w, z and q in L∞(QT ). Moreover, the source
terms are in L2(0, T ;H), according to (3.1)-(3.3) and 0 ≤ φ∗ ≤ 1 a.e. in QT . Therefore, by the
general results concerning the existence and uniqueness of the solutions to linear parabolic systems
(cf. Ref. [57]), we deduce that there is a unique triplet (w, z, q) ∈ X0×X×X solving (4.25)-(4.29)
and satisfying estimate (4.30). 
We introduce the convex closed subsets of L2(QT ):
K1 : = {u ∈ L2(QT ); 0 ≤ u ≤ Umax a.e. in QT },
K2 : = {s ∈ L2(QT ); 0 ≤ s ≤ Smax a.e. in QT }.
We also specify that the normal cone at U∗ to K1 is given by
NK1(U
∗) = {ξ ∈ L2(QT ); (ξ, U∗ − u¯) ≥ 0 for all u¯ ∈ K1}.
Similarly, we denote by NK2(S
∗) the normal cone at S∗ to K2.
Theorem 4.4. Let (U∗, S∗) ∈ Uad be an optimal control for (P ) with the corresponding state
(φ∗, σ∗, p∗). Then, the first order optimality conditions
(k6I +NK1)U
∗ 3 h′(φ∗)w, (4.31)
(k7I +NK2)S
∗ 3 φ∗z (4.32)
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hold true, w and z being the first and third components of the solution (w, z, q) ∈ X0 ×X ×X to
the system (4.25)-(4.29).
Proof. Since (U∗, S∗) ∈ Uad is an optimal control for (P ), then we have that
J(Uµ, Sµ) ≥ J(U∗, S∗), (4.33)
where Uµ and Sµ were defined in (4.7), namely, Uµ = U∗ + µu, Sµ = S∗ + µs, with (u, s) =
(u¯−U∗, s¯− S∗) and (u¯, s¯) arbitrary in Uad. Replacing the expressions of Uµ and Sµ in (4.33), by a
straightforward calculation we obtain the optimality conditions in terms of the solution (Y, Z, P ) of
the system in variations (4.1)-(4.5) corresponding to (u, s). We easily deduce that
k1
∫
QT
(φ∗ − φQ)Y dxdt+ k2
∫
Ω
(φ∗(T )− φΩ)Y (T )dx+ k3
∫
Ω
Y (T )dx
+k4
∫ T
0
[(∫
Ω
p∗(t)dx− pΩ(t)
)+ ∫
Ω
P (t)dx
]
dt+ k5
∫
Ω
P (T )dx
+k6
∫
QT
U∗udxdt+ k7
∫
QT
S∗sdxdt ≥ 0. (4.34)
Now we test (4.1) by w, (4.2) by z, (4.3) by q, sum up and integrate by parts taking into account
the boundary conditions (4.4) and (4.28). Using also the initial conditions (4.5) of the system in
variations and the final conditions (4.29) of the adjoint system, we obtain the equation∫
Ω
(k2(φ
∗(T )− φΩ) + k3)Y (T )dx+
∫
Ω
k5P (T )dx
+
∫ T
0
〈
(−wt − λ∆w + (F ′′(φ∗)−m(σ∗)h′′(φ∗) + U∗h′′(φ∗)w)(t), Y (t)
〉
V ′0 ,V0
dt
+
∫ T
0
〈(γchσ∗z − αchq)(t), Y (t)〉V ′0 ,V0 dt
+
∫ T
0
〈
(−zt − η∆z + (γh + γchφ∗)z −m′(σ∗)h′(φ∗)w)(t), Z(t)
〉
V ′,V dt
+
∫ T
0
〈(−qt −D∆q + γpq)(t), P (t)〉V ′,V dt
=
∫
QT
(−uh′(φ∗)w − sφ∗z) dxdt. (4.35)
Using again the adjoint system (4.25)-(4.27) in (4.35) we obtain
k1
∫
QT
(φ∗ − φQ)Y dxdt+ k2
∫
Ω
(φ∗(T )− φΩ)Y (T )dx+ k3
∫
Ω
Y (T )dx
+k4
∫
QT
(∫
Ω
p∗(t)dx− pΩ(t)
)+
Pdxdt+ k5
∫
Ω
P (T )dx
=
∫
QT
(−uh′(φ∗)w − sφ∗z) dxdt. (4.36)
By comparison between (4.34) and (4.36) we easily deduce∫
QT
(−uh′(φ∗)w − sφ∗z) dxdt+ k6 ∫
QT
U∗udxdt+ k7
∫
QT
S∗sdxdt ≥ 0,
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where (u, s) = (u¯− U∗, s¯− S∗) and (u¯, s¯) is arbitrary in Uad. Therefore, we can write∫
QT
{
(h′(φ∗)w − k6U∗)(U∗ − u¯) + (−k7S∗ + φ∗z)(S∗ − s¯)
}
dxdt ≥ 0, (4.37)
for all (u¯, s¯) ∈ Uad. Then, taking s¯ = S∗ and u¯ arbitrary in (4.37) we obtain (4.31). Finally, setting
u¯ = U∗ and s¯ arbitrary we derive (4.32), as claimed. 
Remark 4.5. We note that the optimality conditions do not depend on the component q of the
solution to the adjoint system. This is essentially due to the biological meaning of the model, because
p, the third component of the state system, does not influence the evolution of the other components
φ and σ, but is a result of their evolution.
Remark 4.6. Let us denote by ProjK(v) the projection of v ∈ L2(QT ) into
K = {ζ ∈ L2(QT ); a ≤ ζ ≤ b a.e. in QT }
defined by
ProjK(v) =

a, if v < a,
v, if a ≤ v ≤ b,
b, if v > b.
(4.38)
We also recall that if (I + κNK)v
∗ 3 v, then
v∗ = (I + κNK)−1v = ProjKv for all κ > 0. (4.39)
Hence, if the coefficients k6 and k7 are positive, then (4.31) and (4.32) entail that
U∗ = ProjK1
(
1
k6
h′(φ∗)w
)
, S∗ = ProjK2
(
1
k7
φ∗z
)
. (4.40)
The relations (4.40) can be written as
U∗ =

0, on the set {h′(φ∗)w < 0},
1
k6
h′(φ∗)w, on the set {0 ≤ h′(φ∗)w ≤ k6Umax},
Umax, on the set {h′(φ∗)w > k6Umax}
(4.41)
and
S∗ =

0, on the set {φ∗z < 0},
1
k7
φ∗z, on the set {0 ≤ φ∗z ≤ k7Smax},
Smax, on the set {φ∗z > k7Smax}.
(4.42)
On the other hand, if a coefficient is zero, let us say, if k6 = 0, (4.31) becomes
NK1(U
∗) 3 h′(φ∗)w, (4.43)
which implies that
U∗

= 0, on the set {h′(φ∗)w < 0},
∈ [0, Umax], on the set {h′(φ∗)w = 0},
= Umax, on the set {h′(φ∗)w > 0}.
(4.44)
A similar result can be deduced for S∗ if k7 = 0.
Remark 4.7. We discuss here how the previous results change in the case that the controllers U
and S are considered time dependent only. This formulation might be more realistic for the therapy
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and, hence we will use it to explore the behavior of the optimal control problem in the simulations
presented in Section 6. First, the functional J becomes
J(U, S) =
k1
2
∫
QT
(φ(t, x)− φQ)2dxdt+ k2
2
∫
Ω
(φ(T, x)− φΩ)2dx+ k3
∫
Ω
φ(T, x)dx
+
k4
2
∫ T
0
[(∫
Ω
p(t, x)dx− pΩ(t)
)+]2
dt+ k5
∫
Ω
p(T, x)dx
+
k6
2
∫ T
0
U2(t)dt+
k7
2
∫ T
0
S2(t)dt
and the minimization problem is
Minimize {J(U, S); (U, S) ∈ Uad},
subject to (2.1)-(2.5), where
Uad = {(u, s) ∈ L∞(0, T )× L∞(0, T ); 0 ≤ u ≤ Umax, 0 ≤ s ≤ Smax, a.e. in (0, T )}.
All existence results in Theorems 3.2, 3.3, 4.2 and Propositions 4.1, 4.3 are conserved. For computing
the optimality conditions we consider the sets
K1 : = {u ∈ L2(0, T ); 0 ≤ u ≤ Umax a.e. in (0, T )},
K2 : = {s ∈ L2(0, T ); 0 ≤ s ≤ Smax a.e. in (0, T )}
and by remaking the calculation from (4.36) we get∫ T
0
{(∫
Ω
h′(φ∗)wdx− k6U∗
)
(U∗ − u¯)
+
(∫
Ω
φ∗zdx− k7S∗
)
(S∗ − s¯)
}
dt ≥ 0. (4.45)
Thus, (4.31)-(4.32) in Theorem 4.4 are replaced by
(k6I +NK1)U
∗ 3
∫
Ω
h′(φ∗)wdx, (4.46)
(k7I +NK2)S
∗ 3
∫
Ω
φ∗zdx. (4.47)
Remark 4.8. For a later use we also recall that from a condition of optimality written as∫ T
0
(dUu+ dSs)dt =
∫ T
0
{dU (u¯− U∗) + dS(s¯− S∗)} dt ≥ 0
we can formally read that
dU = ∇UJ(U∗, S∗), dS = ∇SJ(U∗, S∗), (4.48)
where ∇UJ(U∗, S∗) and ∇SJ(U∗, S∗) are the derivatives of J with respect to the first and second
variables, respectively, calculated at (U∗, S∗). Consequently, we have
dU = ∇UJ(U∗, S∗) = k6U∗ −
∫
Ω
h′(φ∗)wdx, (4.49)
dS = ∇SJ(U∗, S∗) = k7S∗ −
∫
Ω
φ∗zdx. (4.50)
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5 Numerical method
5.1 Spatial discretization
We use Isogeometric Analysis [37], a recent generalization of Finite Element Analysis, to discretize
in space the forward and adjoint problems. Our spatial discretization of the forward problem is based
on the following weak form of Eqns. (2.1)–(2.3): find φ ∈ V0, σ ∈ V , and p ∈ V , such that
Bχ1 (χ1, φ, σ, p) = 0 for all χ1 ∈ V0, (5.1)
Bχ2 (χ2, φ, σ, p) = 0 for all χ2 ∈ V, (5.2)
Bχ3 (χ3, φ, σ, p) = 0 for all χ3 ∈ V, (5.3)
where
Bχ1 (χ1, φ, σ, p) =
∫
Ω
χ1
[
φt + F
′(φ) + h′(φ)(U −m(σ))] dx+ ∫
Ω
λ∇χ1 · ∇φdx, (5.4)
Bχ2 (χ2, φ, σ, p) =
∫
Ω
χ2 [σt + γhσ + γchσφ− Sh(1− φ)− (Sc − S)φ] dx
+
∫
Ω
η∇χ2 · ∇σdx, (5.5)
Bχ3 (χ3, φ, σ, p) =
∫
Ω
χ3 [pt + γpp− αh − αchφ] dx+
∫
Ω
D∇χ3 · ∇pdx. (5.6)
We also introduce a weak form of the adjoint problem defined by Eqns. (4.25)–(4.27), which is stated
as: find w ∈ V0, z ∈ V , and q ∈ V such that
Bψ1 (ψ1, w, z, q) = 0 for all ψ1 ∈ V0, (5.7)
Bψ2 (ψ2, w, z, q) = 0 for all ψ2 ∈ V, (5.8)
Bψ3 (ψ3, w, z, q) = 0 for all ψ3 ∈ V, (5.9)
where,
Bψ1 (ψ1, w, z, q) =−
∫
Ω
ψ1wtdx+
∫
Ω
λ∇ψ1 · ∇wdx+
∫
Ω
ψ1 [γchσ
∗ + (S∗ − Sch)] zdx
+
∫
Ω
ψ1
[
F ′′(φ∗) + h′′(φ∗)(U∗ −m(σ∗))]wdx− ∫
Ω
ψ1αchqdx
−
∫
Ω
ψ1k1(φ
∗ − φQ)dx, (5.10)
Bψ2 (ψ2, w, z, q) =−
∫
Ω
ψ2ztdx+
∫
Ω
η∇ψ2 · ∇zdx+
∫
Ω
ψ2z (γh + γchφ
∗) dx
−
∫
Ω
ψ2wm
′(σ∗)h′(φ∗)dx, (5.11)
Bψ2 (ψ2, w, z, q) =−
∫
Ω
ψ3qtdx+
∫
Ω
D∇ψ3 · ∇qdx+
∫
Ω
ψ3qγpdx
−
∫
Ω
ψ3k4 (P
∗ − PΩ)+ dx. (5.12)
The above-defined weak forms are discretized by defining finite-dimensional spaces V h ⊂ V and
V h0 ⊂ V0. We construct the discrete spaces using C1-continuous quadratic B-splines [37]. The space
V h is defined as V h = span{NA}A=1,...,nb , where nb = dim(V h) and the NA’s are multivariate
splines. We use the superscript h to denote finite-dimensional approximations to the exact solution
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of the forward and adjoint problems. For example, φh(t, x) =
∑nb
A=1 φA(t)NA(x), where the φA’s,
called control variables, are the unknowns of the problem. The functions σh, ph, wh, zh, and qh are
defined analogously. The functions that belong to V h0 will have some control variables constrained to
ensure that Dirichlet boundary conditions are satisfied. The Neumann boundary conditions relevant
to this problem are naturally enforced within the weak form.
5.2 Time integration
Our time integration scheme is based on the generalized-α algorithm [13, 44]. Let us call Φ the global
vector of degrees of freedom associated with the unknown φh, i.e., Φ = {φA}A=1,...,nb . Likewise,
we will also make use of the vectors Σ = {σA}A=1,...,nb and P = {pA}A=1,...,nb . We introduce the
residual vector for the forward problem
ResF = {Rφ,Rσ,Rp} (5.13)
where Rφ = {RφA}A=1,...,nb , Rσ = {RσA}A=1,...,nb , and Rp = {RpA}A=1,...,nb , such that
RφA = B
χ
1 (NA,Φ,Σ,P ), (5.14)
RσA = B
χ
2 (NA,Φ,Σ,P ), (5.15)
RpA = B
χ
3 (NA,Φ,Σ,P ). (5.16)
We call Un = {Φn,Σn,P n} the time-discrete approximation to the control variables of the forward
problem at time tn. In the forward problem, we calculate Un+1 from Un by enforcing the equation
ResF(U˙n+αm ,Un+αf ) = 0, (5.17)
where
Un+1 =Un + (tn+1 − tn)U˙n + γ(tn+1 − tn)(U˙n+1 − U˙n), (5.18)
U˙n+αm= U˙n + αm(U˙n+1 − U˙n), (5.19)
Un+αf =Un + αf (Un+1 −Un). (5.20)
Here, tn+1 − tn = ∆tn > 0 is the time step, and αm, αf , and γ are real-valued parameters that
define the accuracy and stability of the algorithm.
For the adjoint problem, we define the global vectors of degrees of freedom W , Z, and Q,
corresponding, respectively, to the discrete functions wh, zh, and qh. The residual vector for the
adjoint problem is
ResA = {Rw,Rz,Rq} (5.21)
where Rw = {RwA}A=1,...,nb , Rz = {RzA}A=1,...,nb , and Rq = {RqA}A=1,...,nb , such that
RwA = B
ψ
1 (NA,W ,Z,Q), (5.22)
RzA = B
ψ
2 (NA,W ,Z,Q), (5.23)
RqA = B
ψ
3 (NA,W ,Z,Q). (5.24)
Let us call Y n = {W n,Zn,Qn} the global vector of degrees of freedom for the adjoint problem at
t = tn. The adjoint problem is solved backwards in time starting from data at t = T , so for this
problem ∆tn = tn − tn+1 < 0. The equation that allows us to determine Y n from Y n+1 is
ResA(Y˙ n+αm ,Y n+αf ) = 0 (5.25)
17
where
Y n =Y n+1 + (tn − tn+1)Y˙ n+1 + γ(tn − tn+1)(Y˙ n − Y˙ n+1), (5.26)
Y˙ n+αm= Y˙ n+1 + αm(Y˙ n − Y˙ n+1), (5.27)
Y n+αf =Y n+1 + αf (Y n − Y n+1). (5.28)
As shown in [44], the generalized-α algorithm can be made A-stable and second-order accurate by
taking ρ∞ ∈ [0, 1] and
αm =
1
2
(
3− ρ∞
1 + ρ∞
)
, αf =
1
1 + ρ∞
, γ =
1
2
+ αm − αf . (5.29)
All the calculations presented in this paper were performed taking ρ∞ = 1/2 and using Eq. (5.29).
We linearized the nonlinear algebraic equations defined by (5.17)–(5.20) and (5.25)–(5.28) by using
the Newton-Raphson algorithm. The convergence criterion to advance from one time step to the
next one was that the individual residuals (e.g., Rφ, Rσ, and Rp for the forward problem) are
reduced to NL of its initial value. The linear systems that result after linearization are solved using
GMRES [80] with diagonal preconditioner up to a predefined tolerance L or a maximum number of
iterations.
5.3 Optimal control algorithm
We solve numerically the optimal control problem using the steepest-descent gradient method; see,
e.g., Ref. [3] (Algorithm 2.2). As noted in Remark 4.7, we will consider the controls U and S
to be exclusively time-dependent in our simulations, and so we build the steepest-descent gradient
algorithm accordingly here. We determine the optimal functions U and S constructing a sequence
of approximations {Uk}k≥1 and {Sk}k≥1 with U0 and S0 given. In what follows, we describe our
algorithm to calculate (Uk+1, Sk+1) from (Uk, Sk), which involves 7 main steps:
Step 1: Compute the functions (φk, σk, pk) solving the forward problem (2.1)–(2.5) with U = Uk
and S = Sk.
Step 2: Compute the functions (wk, zk, qk) solving the adjoint problem (4.25)–(4.29) with
(U∗, S∗) = (Uk, Sk) and (φ∗, σ∗, p∗) = (φk, σk, pk).
Step 3: Evaluate the gradient of J at (Uk, Sk) using Eqns. (4.49)–(4.50), i.e.,
dUk = ∇UJ(Uk, Sk) = k6Uk −
∫
Ω
h′(φk)wkdx (5.30)
dSk = ∇SJ(Uk, Sk) = k7Sk −
∫
Ω
φkzkdx. (5.31)
Step 4: Check if any of the following convergence criteria is satisfied:
Criterion 1:
||dUk ||2L2(0,T ) < εSD1||dU0 ||2L2(0,T ),
||dSk ||2L2(0,T ) < εSD1||dS0 ||2L2(0,T ) (5.32)
Criterion 2:
||dUk − dUk−1 ||2L2(0,T ) < εSD2||dUk−1 ||2L2(0,T ),
||dSk − dSk−1 ||2L2(0,T ) < εSD2||dSk−1 ||2L2(0,T ) (5.33)
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where εSD1 and εSD2 are predefined tolerances. If any of the convergence criteria is satisfied, the
iterative process to compute the optimal functions ends. If none of the convergence criteria are
satisfied, we proceed to Step 5.
Step 5: Compute a pool of potential values for (Uk+1, Sk+1) using the updates
Uk,µj = Uk − µjdUk for j = 1, . . . , Nµ (5.34)
Sk,µj = Sk − µjdSk for j = 1, . . . , Nµ (5.35)
where µj = j/Nµ with j = 1, . . . , Nµ. Here, Nµ > 1 is an integer parameter of the algorithm.
Step 6: Select the best functions in the pool {Uk+1,µj}j=1,...,Nµ , {Sk+1,µj}j=1,...,Nµ finding j∗
such that
J(Uk+1,µj∗ , Sk+1,µj∗ ) = minj=1,...,Nµ
{J(Uk+1,µj , Sk+1,µj )}. (5.36)
Step 7: Define the (k + 1)th iteration as
Uk+1 = Uk+1,µj∗ (5.37)
Sk+1 = Sk+1,µj∗ . (5.38)
This completes one iteration of the steepest descent algorithm. The process is then repeated until
one of the convergence criteria defined in Step 4 is satisfied or a predefined maximum number of
iterations is reached.
6 Simulation study of the optimal control problem
6.1 Description
In this section, we explore the behavior of the optimal control problem stated in Section 2.2 for
time-dependent controls U(t) and S(t). To this end, we carry out a simulation study featuring a
prostatic tumor treated with combined cytotoxic and antiangiogenic therapy. Thus, the aim of these
simulations is to compute the optimal drug-na¨ıve cytotoxic and antiangiogenic effects, U(t) and S(t),
respectively, to effectively treat the tumor according to our model of PCa growth. We run this study
over the time of a single cycle of combined therapy with docetaxel and bevacizumab, i.e., T = 21
days [16, 48, 68]. In Section 7 we will use the results of this study to explore alternative therapeutic
strategies for specific drugs.
In the following, we present values of the model parameters used in the simulations, the choice
of terms and corresponding weighting constants in the objective functional J , the construction of
initial guesses and the admissible space for U(t) and S(t), and the computational details of the
specific implementation of the algorithms presented in Section 5 for this simulation study.
6.1.1 Parameters of the PCa growth model
We consider an aggressive case of PCa. This scenario corresponds to a tumor having a high Gleason
score, which is a routine clinical variable associated to cancer aggressiveness [68]. To model this
instance of PCa growth, we select ρ and A in Eq. (2.7) based on the average values of tumor cell
proliferation and apoptosis, tumor doubling times, and serum PSA doubling times previously reported
in the literature for tumors with high Gleason score [7, 16, 82].
The values of the other parameters in our PCa growth model have been adopted from previous
studies [16, 59–61, 99]. Table 1 summarizes the parameters participating in Eqns. (2.1)–(2.3) and
their values in the simulation study presented herein.
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Table 1: List of parameters in Eqns. (2.1)–(2.3) and their corresponding values in the simulations presented herein.
Parameter Notation Value Reference
Tumor dynamics
Diffusivity of the tumor phase field λ 640 µm2/day [61, 99]
Tumor mobility M 2.5 1/day [61, 99]
Net proliferation scaling factor mref 7.55·10−2 1/day [99]
Scaling reference for proliferation rate K¯ρ 1.50·10−2 1/day [7, 82]
Proliferation rate Kρ 1.50·10−2 1/day [7, 82]
Scaling reference for apoptosis rate K¯A 2.10·10−2 1/day [7, 82]
Apoptosis rate KA 1.37·10−2 1/day [7, 82]
Nutrient dynamics
Nutrient diffusivity η 6.4 · 104 µm2/day [61]
Nutrient supply in healthy tissue Sh 2 g/L/day [61]
Nutrient supply in tumor tissue Sc 2.75 g/L/day [61]
Nutrient uptake by healthy tissue γh 2 g/L/day [16]
Nutrient uptake by tumor tissue γc 17 g/L/day [16]
Tissue PSA dynamics
Tissue PSA diffusivity D 640 µm2/day [61]
Healthy tissue PSA production rate αh 1.712·10−2 ng/mL/cc/day [61]
Tumoral tissue PSA production rate αc αc = 15αh [61]
Tissue PSA natural decay rate γp 0.274 1/day [61]
6.1.2 Objective functional
As explained in Section 2.2, we selected only some ki, i = 1, . . . , 7 to be nonzero in our simulations.
In particular, we consider three versions of the functional J defined in Eq. (2.8) corresponding to
three different sets of nonzero constants ki, i = 1, . . . , 7, as follows:
J1(U, S) =
k1
2
∫
QT
(φ(t, x)− φQ)2dxdt+ k2
2
∫
Ω
(φ(T, x)− φΩ)2dx
+
k4
2
∫ T
0
[(∫
Ω
p(t, x)dx− pΩ(t)
)+]2
dt
+
k6
2
∫ T
0
U2(t)dt+
k7
2
∫ T
0
S2(t)dt, (6.1)
J2(U, S) =
k2
2
∫
Ω
(φ(T, x)− φΩ)2dx+ k4
2
∫ T
0
[(∫
Ω
p(t, x)dx− pΩ(t)
)+]2
dt
+
k6
2
∫ T
0
U2(t)dt+
k7
2
∫ T
0
S2(t)dt, (6.2)
and
J3(U, S) = k3
∫
Ω
φ(T, x)dx+
k4
2
∫ T
0
[(∫
Ω
p(t, x)dx− pΩ(t)
)+]2
dt
+
k6
2
∫ T
0
U2(t)dt+
k7
2
∫ T
0
S2(t)dt. (6.3)
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We choose φQ = 0 and φΩ = 0, such that the optimization problem aims at killing the tumor.
Consequently, we set pΩ = αhvol(Ω)/γp, which is the value of serum PSA that would be obtained
if the complete computational domain Ω were comprised of healthy tissue. We did not consider the
term multiplied by k5 in the original definition of J in Eq. (2.8) because, in general, serum PSA can
be obtained with reasonable time resolution in experimental and clinical settings [68].
In this simulation study, we will explore the performance of our optimal control formulation under
an array of values of the weighting constants in J1, J2, and J3. In simulations with J1, we impose
k1 = k2 due to the similarity of the terms with k1 and k2. Indeed, notice that the term with k2
introduces in the transversality condition for the adjoint variable w (Eq. (4.29)) a similar term to the
forcing induced by the k1 term in the equation for w (Eq. (4.25)). We further choose k4 = k1 such
that we use the same weighting for the terms accounting for tumor volume and serum PSA in the
objective functional. Likewise, we impose k4 = k2 and k4 = k3 for J2 and J3, respectively. We also
fix k6 = 1 and k7 = 1 in all simulations in Section 6.3, such that we do not favor one therapy over
the other within our modeling framework. These choices make J1, J2, and J3 solely dependent on
k1, k2, and k3, respectively; which facilitates the analysis of this first simulation study of the optimal
control problem presented herein. The specific values of the weighting constants employed in each
simulation are reported along with the corresponding results in Section 6.3.
6.1.3 Initial guess and maximum values of the controls
Pharmacodynamic studies of common cytotoxic and antiangiogenic drugs for cancer treatment usually
show an exponential decay in drug concentration following the systemic delivery of the prescribed
dose [4, 27, 62, 90]. Additionally, previous efforts to model cytotoxic and antiangiogenic drug effects
usually rely on a linear dependence on the drug concentration [6, 8, 14, 16, 25, 34, 46, 50, 77].
We adopted this approach for the formulation of the initial guess of cytotoxic drug effects on tumor
dynamics U0(t), which is hence given by
U0(t) = mrefβcdce
− t
τc , (6.4)
where βc measures the effect of the cytotoxic drug on tumor dynamics per unit of drug dose de-
livered, dc is the prescribed dose of the cytotoxic drug, and τc stands for the mean lifetime of the
chemotherapeutic drug. Likewise, we define the initial guess of the antiangiogenic effect on nutrient
supply S0(t) as
S0(t) = βadae
− t
τa , (6.5)
where βa measures the effect of the antiangiogenic drug on the nutrient supply per unit of drug
dose delivered, da is the prescribed dose of antiangiogenic drug, and τa denotes the mean lifetime of
the antiangiogenic drug. Notice that this choice of U0(t) and S0(t) matches our previous modeling
approach [16]. Additionally, observe that under the assumption of linear dependence of U(t) and
S(t) on the cytotoxic and antiangiogenic drug concentrations, respectively, the last two terms in our
optimal control problem functional J in Eq. (2.8) are penalizing large concentrations of cytotoxic
and antiangiogenic drugs [6, 8, 14, 16, 25, 34, 46, 50, 77].
Docetaxel is considered the gold standard drug in cytotoxic chemotherapy of advanced PCa [19,
48, 68]. Additionally, bevacizumab has been extensively investigated in single-drug antiangiogenic
or combined cytotoxic-antiangiogenic drug protocols for advanced PCa [2, 48, 76]. Therefore, we
use the standard dosage and pharmacodynamic properties of these two drugs to calculate U0(t) and
S0(t) in our simulations, respectively. The values of the parameters involved in the dynamics of drug
effects in Eqns. (6.4)-(6.5) are provided in Table 2.
Additionally, the admissible values of the controls U(t) and S(t) are respectively bounded by
maximum values Umax and Smax in our formulation of the optimal control problem (see Section 2.2).
We set Umax = 0.012 1/day and Smax = 0.80 g/L/day. These values respectively correspond to
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Table 2: List of parameters in the definition of the initial guess for the controls U0(t) and S0(t) given in Eqns. (6.4)-(6.5)
and their corresponding values.
Parameter Notation Value Reference
Cytotoxic chemotherapy
Mean lifetime of cytotoxic drug τc 5 days [4, 90]
Cytotoxic drug effect βc 1.59·10−2 1/(mg/m2) [16]
Cytotoxic drug dose dc 75 mg/m
2 [48, 68]
Antiangiogenic therapy
Mean lifetime of antiangiogenic drug τa 30 days [27, 62]
Antiangiogenic drug effect βa 0.04 g/L/day/(mg/kg) [16]
Antiangiogenic drug dose da 15 mg/kg [2, 48]
a maximum dose of 100 mg/m2 of docetaxel and 20 mg/kg of bevacizumab under the modeling
assumptions of Eqns. (6.4)-(6.5) [20, 31, 47, 64, 67].
While we have used docetaxel and bevacizumab to define U0(t), S0(t), Umax, and Smax, we want
to remark that the optimal controls U(t) and S(t) describe the optimal cytotoxic and antiangiogenic
effects according to our PCa growth model, which may also be obtained with different dosages of
other drugs showing different pharmacodynamics. In Section 7, we provide and example of how to
estimate some drug protocols that would approximately yield the optimal U(t) and S(t) obtained in
the simulations of our optimal control problem.
6.2 Computational setup
We implemented the numerical algorithms introduced in Section 5 to resolve the forward problem, the
adjoint problem, and the steepest descent gradient method by extending our in-house isogeometric
codes to simulate PCa growth [59–61]. These codes were built following the general directions in
[37].
6.2.1 Space and time discretization
The computational domain in all simulations is a square with side length of Ld = 3000 µm and 256
isogeometric elements per side. The time step was set to a constant value of ∆tn = 0.1 days for the
forward problem and ∆tn = −0.1 days for the adjoint problem.
6.2.2 Convergence of numerical algorithms
The convergence of the Newton-Raphson method was set to tolerance εNL = 10
−3, while for the
GMRES algorithm was set to εL = 10
−3 or a maximum of 500 iterations. The convergence for
the steepest-descent gradient algorithm was set to εSD1 = εSD2 = 10
−6 or a maximum of 100
iterations. To find the update for the optimal U(t) and S(t) in each step of the steepest-descent
gradient algorithm, we evaluated Nµ = 10 evenly-spaced values of µ in (0, 1], i.e., µj = j/10 for
j = 1, . . . , 10 (see Section 5.3).
6.2.3 Initial conditions of the forward problem
We approximate the initial tumor phase field as an ellipsoidal tumor placed in the center of the
domain with semiaxes a = 150 µm and b = 200 µm parallel to the domain sides. We implement this
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initial condition by L2-projecting the hyperbolic tangent function
φ0(x) = φ0(x1, x2) = 0.5− 0.5 tanh
(
10
(√
(x1 − Ld/2)2
a2
+
(x2 − Ld/2)2
b2
− 1
))
(6.6)
over the quadratic B-spline space supporting our spatial discretization. This operation yields the
control variables φ0,A = φA(0), A = 1, . . . , nb, for the spline representation of the phase-field initial
condition, i.e., φh0(x) = φ
h(0, x) =
∑nb
A=1 φ0,ANA(x) (see Section 5.1).
The initial conditions for the nutrient and the tissue PSA are estimated from φ0 as
σ0 = c
0
σ + c
1
σφ0 (6.7)
and
p0 = c
0
p + c
1
pφ0. (6.8)
The constants c0σ, c
1
σ, c
0
p, and c
1
p are computationally estimated [60], such that σ0 and p0 represent
a constant value of the nutrient and tissue PSA within the tumor and the host tissue. Hence, we
choose c0σ = 1 g/L, c
1
σ = −0.8 g/L, c0p = 0.0625 ng/mL/cc, and c1p = 0.7975 ng/mL/cc.
In all simulations, we initially let the tumor grow untreated for 60 days, i.e., U(t) = 0 and
S(t) = 0. This enables us to have a reference for the dynamics of the untreated tumor and obtain
a good estimate of fields φ, σ, and p according to our PCa growth model away from the estimated
initial conditions [16]. Then, we proceed to add cytotoxic and antiangiogenic drug effects. To
facilitate the ensuing implementation of the steepest-descent algorithm, we reset t = 0 at the date
of drug delivery and we use the values of φ, σ, and p obtained at the end of the untreated growth
phase as initial conditions for the forward problem within our optimal control framework. Hence,
the forward and dual problems are run between t = 0 and t = T = 21 days, corresponding to the
common duration of a combined therapy cycle for PCa [16, 48, 68].
6.3 Simulation results of the optimal control problem
Figures 1–3 respectively show the optimal U(t) and S(t) distributions that we obtained in simulations
of our optimal control problem using the objective functionals J1, J2, and J3 for an array of values
of k1, k2, and k3. These figures also depict the evolution of tumor volume and serum PSA obtained
for each optimal solution, along with the tumor contours corresponding to the isosurface φ = 0.5 at
t = T . Larger values of the driving weighting constant ki, i = 1, 2, 3, in each corresponding objective
functional Ji, i = 1, 2, 3, increasingly penalize tumor volume and serum PSA (see Section 6.1.2).
Consequently, the minimization of Ji, i = 1, 2, 3, will require at least one of the controls to also
increase for larger choices of ki, i = 1, 2, 3, because this provides a more intense inhibitory effect on
tumor dynamics that ultimately leads to smaller tumor volume and lower serum PSA, as shown in
Figs. 1–3.
In all cases run with J1, the optimal therapy obtained in our simulations involves only a monoton-
ically decreasing cytotoxic effect and virtually no antiangiogenic effect, i.e., S(t) ≈ 0. The optimal
cytotoxic effect even saturates to Umax at early times for k1 = 5, whereas S(t) still takes negligible
values. Thus, these results suggest that strong cytotoxic effects suffice to optimally control the vol-
ume and serum PSA of the simulated tumor according to our PCa model. A similar result is obtained
for the simulations involving J2 and J3 depicted in Figs. 2–3. However, the optimal cytotoxic effects
U(t) obtained for functionals J2 and J3 are approximately constant for early times and increase in
time towards t = T , especially for large values of k2 and k3. As the tumor phase field φ drives serum
PSA dynamics in our PCa model (see Section 2.1), the tumor volume becomes the most powerful
clinical quantity of interest participating in the objective functional J . Therefore, the increase in
optimal U(t) by t = T for larger k2 and k3 is a consequence of J2 and J3 controlling for tumor
volume only at t = T .
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Figure 1: Results of the optimal control problem using functional J1 for k1 = 1, 2, 3, 4, 5. (A) Optimal cytotoxic
effects U(t) obtained for each value of k1 compared to standard docetaxel therapy (U0(t), gray dotted line) and the
corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines). (B) Top: optimal
antiangiogenic effects S(t) obtained for each value of k1 compared to standard bevacizumab therapy (S0(t), gray
dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines).
Bottom: Detail of optimal S(t) for k1 = 1, 3, 5 calculated numerically (solid lines) and with Eq. (4.45) (dashed lines).
(C) Evolution of tumor volume vφ (top) and serum PSA Ps (bottom) using the optimal U(t) and S(t) obtained via
simulation for each value of k1 compared to standard combined therapy, i.e., vφ,0 and Ps,0 respectively (gray dotted
lines). (D) Tumor contours obtained at t = T using the optimal U(t) and S(t) obtained via simulation for each value
of k1. The gray area denoted with φ0 is the tumor region at the onset of the optimal control problem (t = 0). The
black line is the tumor contour at t = T for the standard combined therapy (U0, S0).
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Figure 2: Results of the optimal control problem using functional J2 for k2 = 1, 10, 20, 40, 100. (A) Optimal cytotoxic
effects U(t) obtained for each value of k2 compared to standard docetaxel therapy (U0(t), gray dotted line) and the
corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines). (B) Top: optimal
antiangiogenic effects S(t) obtained for each value of k2 compared to standard bevacizumab therapy (S0(t), gray
dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines).
Bottom: Detail of optimal S(t) for k2 = 1, 20, 100 calculated numerically (solid lines) and with Eq. (4.45) (dashed
lines). (C) Evolution of tumor volume vφ (top) and serum PSA Ps (bottom) using the optimal U(t) and S(t) obtained
via simulation for each value of k2 compared to standard combined therapy, i.e., vφ,0 and Ps,0 respectively (gray dotted
lines). (D) Tumor contours obtained at t = T using the optimal U(t) and S(t) obtained via simulation for each value
of k2. The gray area denoted with φ0 is the tumor region at the onset of the optimal control problem (t = 0). The
black line is the tumor contour at t = T for the standard combined therapy (U0, S0).
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Figure 3: Results of the optimal control problem using functional J3 for k3 = 1, 5, 10, 20, 50. (A) Optimal cytotoxic
effects U(t) obtained for each value of k3 compared to standard docetaxel therapy (U0(t), gray dotted line) and the
corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines). (B) Top: optimal
antiangiogenic effects S(t) obtained for each value of k3 compared to standard bevacizumab therapy (S0(t), gray
dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45) (overlapping white dashed lines).
Bottom: Detail of optimal S(t) for k3 = 1, 10, 50 calculated numerically (solid lines) and with Eq. (4.45) (dashed
lines). (C) Evolution of tumor volume vφ (top) and serum PSA Ps (bottom) using the optimal U(t) and S(t) obtained
via simulation for each value of k3 compared to standard combined therapy, i.e., vφ,0 and Ps,0 respectively (gray dotted
lines). (D) Tumor contours obtained at t = T using the optimal U(t) and S(t) obtained via simulation for each value
of k3. The gray area denoted with φ0 is the tumor region at the onset of the optimal control problem (t = 0). The
black line is the tumor contour at t = T for the standard combined therapy (U0, S0).
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The simulations presented in Figs. 1–3 show that our optimal control problem enables the calcu-
lation of an optimal U(t) providing a similar control of tumor volume and serum PSA as the standard
combined therapy with docetaxel and bevacizumab, i.e., U0(t) and S0(t) respectively. Figures 1–3
also show that we can obtain optimal U(t) and S(t) exhibiting an improved therapeutic performance
over the standard combined protocol as we increase the driving weighting constant ki, i = 1, 2, 3.
However, we notice that the optimal U(t) obtained with J2 and J3 would require a prolonged expo-
sition to the cytotoxic drug. This would entail a high toxicity that may eventually provoke serious
side-effects and may potentially lead to abort the treatment prematurely. Because J1 accounts for
tumor volume for all times, we believe that this objective functional enables the computation of
superior optimal drug effects precisely tuning treatment to tumor dynamics. We note that the curves
of optimal cytotoxic effects U(t) shown in Fig. 1 do not resemble the exponential trends usually
caused by the pharmacodynamics of usual cytotoxic drugs, e.g., the docetaxel curve corresponding
to U0(t) in Figs. 1–3. In Section 7, we illustrate how these optimal U(t) time distributions can be
leveraged to design novel drug protocols.
Additionally, Figures 1–3 show that the optimal U(t) found in our simulations matches the
corresponding theoretical formulation in Eq. (4.45) for each value of the driving weighting constant
ki, i = 1, 2, 3, in Ji, i = 1, 2, 3, respectively. Figures 1–3 also show a detail of optimal S(t)
distributions computed numerically and using the theoretical formulation from Eq. (4.45) for some
simulations. In general, these two optimal S(t) distributions differ in a value that would not be
captured by the tolerance of our implementation of the steepest-descent gradient algorithm (see
Section 5). However, the numerical and theoretical solutions for k1 = 5 virtually coincide. We
also observe increasingly better agreement between both distributions for larger values of the driving
weighting constant ki, i = 1, 2, 3, respectively in Ji, i = 1, 2, 3. Hence, further reducing the
tolerance in the steepest-descent gradient algorithm would make both distributions of optimal S(t)
converge. Nevertheless, we want to remark that both the theoretical and numerical optimal coincide
for therapeutic purposes here, as both expressions of S(t) ≈ 0 regardless of the objective functional
considered.
Finally, Appendix B shows ancillary simulations in which we decrease k7 by several orders of
magnitude using Ji, i = 1, 2, 3. For each of the objective functionals, simulations with k7 = 0.01
and k7 = 0.001 render a non-negligible optimal S(t) that matches the corresponding theoretical
estimates provided by Eq. (4.45). For the simulations with J1 these optimal S(t) solutions show a
decreasing profile in time, while for J2 and J3 the corresponding optimal S(t) solutions are mostly
constant or slightly increasing towards t = T . The optimal cytotoxic effects U(t) remain practically
constant in all simulations for each choice of the objective functional as we vary k7 and the time
distribution is virtually the same as the corresponding simulations shown in Figs. 1–3. However,
the increase of optimal S(t) has limited effect on tumor volume and serum PSA compared to the
parallel increase observed in optimal U(t) in Figs. 1–3. This suggests that the choices of k7 in
Appendix B might artificially bias our optimal control problem and produce unrealistic solutions of
limited therapeutic use. As we discuss in Section 8, a rigorous analysis of the values of the weighting
constants ki, i = 1, . . . , 7, is required to identify choices representing clinically relevant scenarios for
our optimal control framework.
7 Design of drug protocols inspired by the computed optimal effects
7.1 Methodology
To illustrate the applicability of the results of our optimal control problem, we calculate an array of
model-inspired drug protocols aiming at producing the optimal cytotoxic effect U(t) obtained in one
of the simulations of our optimal control problem reported in Section 6. In this section, we assume
S(t) = 0, in accordance with the results showed in the previous one.
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Table 3: Parameter values obtained in the nonlinear fitting with the trust-region method for each investigated drug
protocol.
Parameters dc,1 dc,2 dc,3 tc,2 tc,3 τc
(Units) (mg/m2) (mg/m2) (mg/m2) (day) (day) (day)
1-dose docetaxel 82.53 - - - - -
3-dose docetaxel 73.69 27.97 12.72 6.20 12.04 -
1-dose new drug 59.45 - - - - 12.04
3-dose new drug 58.49 9.20 5.03 2.85 7.90 9.16
We consider four different drug protocols, which we model leveraging the same paradigm that
we employed to define U0(t) in Eq. (6.4). We consider a single dose of docetaxel, for which we
simply calculate dc in Eq. (6.4). Then, we consider a new design drug for which we compute τc and
the docetaxel equivalent dose dc, such that we can use the same βc in Eq. (6.4). Finally, we will
consider a three-dose protocol of either docetaxel or the new design drug. In this case, we extend
the formulation of Eq. (6.4) to
U(t) =
3∑
i=1
mrefβcdc,ie
− t−tc,i
τc H(t− tc,i), (7.1)
where H(t) is the Heaviside function. We compute the three doses dc,i, i = 1, 2, 3 for either drug,
together with τc for the new design drug. Additionally, while we fix the delivery of the first dose at
tc,1 = 0, we calculate the delivery times of the second and third doses for either drug as well (i.e.,
tc,2 and tc,3, respectively).
We compute each of these drug protocols by running a nonlinear least-square fit of the optimal
U(t) obtained using J1(U, S) and k1 = k2 = k4 = 2, which is shown in Fig. 1. We use the
trust-region method as provided by the Curve Fitting Toolbox in MATLAB (Release R2020a, The
Mathworks, Inc., Natick, Massachusetts, US). The starting dose is set at dc = 75 mg/m
2 in single-
dose protocols. In 3-dose protocols the starting point is three equal doses dc = 25 mg/m
2 delivered
weekly, i.e., with tc,2=7 days and tc,3=14 days. The starting value for τc for the new design drug is
5 days, corresponding to docetaxel (see Table 2). The admissible value ranges are [0, 100] mg/m2
for drug doses, [0, 21] for the delivery times of the second and third doses in 3-dose protocols, and
[1, 20] for the characteristic decay time of the new design drug. Additionally, we run a simulation
of the forward problem with the fitted drug protocols using the computational setup described in
Section 6.2 and compare the dynamics of tumor volume and serum PSA with those provided by
the optimal U(t). We assess the goodness of fit by means of R2 and the root mean squared error
(RMSE).
7.2 Results
Table 3 shows the result of the nonlinear fitting of the parameters participating in the formulation of
each protocol. Figure 4 shows the cytotoxic effects generated by each of the investigated protocols,
as well as the tumor volume and serum PSA evolution that they would produce according to the
corresponding forward simulations of our PCa growth model. Table 4 shows the fit quality of the
cytotoxic effects, tumor volume, and serum PSA for each protocol with respect to those provided by
the optimal U(t). The single-dose docetaxel protocol uses a slightly larger dose than the standard
protocol (75 mg/m2, see Table 2), but, in absence of the antiangiogenic drug, the corresponding
control of tumor volume and serum PSA is poorer than in the standard protocol. The single-dose
docetaxel protocol also produced the worse fitting of the optimal cytotoxic effects. Conversely, the
3-dose docetaxel protocol produces an enhanced fitting of the optimal U(t) and a good control of
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Figure 4: Design of drug protocols with docetaxel (Dtx) or a new design drug (New) aiming at reproducing the
optimal cytotoxic effect U∗(t) as obtained from the simulation of our optimal control problem using J1(U, S) and
k1 = k2 = k4 = 2. (A) Cytotoxic drug-induced effects for each of the calculated protocols compared to those of the
standard docetaxel protocol U0(t) and the target optimal cytotoxic effects obtained in our simulations of the optimal
control problem U∗(t). (B) Evolution of tumor volume vφ and serum PSA Ps for each calculated drug protocol, the
standard docetaxel protocol (vφ,0, Ps,0), and the optimal control problem solution (v
∗
φ, P
∗
s ).
Table 4: Fit quality of optimal cytotoxic effects, tumor volume control, and serum PSA control for each investigated
drug protocol.
Cytotoxic effects Tumor volume Serum PSA
Statistic R2 RMSE R2 RMSE R2 RMSE
(Units) (-) (1/day) (-) (cc) (-) (ng/mL)
1-dose docetaxel 0.216 1.58 · 10−2 0.250 3.95 · 10−4 0.676 2.40 · 10−4
3-dose docetaxel 0.786 8.32 · 10−3 0.950 1.03 · 10−4 0.975 6.70 · 10−5
1-dose new drug 0.959 3.62 · 10−3 0.994 3.63 · 10−5 0.997 2.40 · 10−5
3-dose new drug 0.976 2.78 · 10−3 0.999 1.69 · 10−5 0.999 1.02 · 10−5
tumor volume and serum PSA. The best fitting of optimal cytotoxic effects and tumor control was
provided by the protocols involving a new design drug. Our calculations suggest that this design
drug should have a larger τc, approximately twice the corresponding value for docetaxel. This results
in slower decay and hence a prolonged cytotoxic effect in time in comparison to docetaxel. We also
observe that this new drug would require lower dosage for both the single-dose and 3-dose cases
compared to the corresponding protocols using docetaxel. Since the control of tumor volume and
serum PSA is virtually the same with the single-dose and 3-dose protocols using the new design
drug, we believe that the single-drug protocol would be more suitable for clinical implementation as
it would require less visits of the patient to the clinic.
8 Conclusions
We present an optimal control theory enabling the calculation of the optimal drug-na¨ıve cytotoxic and
antiangiogenic effects aiming at successfully treating advanced PCa, which can then be used to design
optimal drug compounds and delivery plans. We build this framework departing from our model of
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PCa growth with cytotoxic and antiangiogenic drug therapies [16]. We define an objective functional
featuring diverse measurements of tumor morphology, tumor volume, and serum PSA, which are
common quantities of interest in experimental and clinical studies of advanced PCa. The functional
contains terms accounting for the differences between the computed solution for the prostate tumor
or PSA and prescribed values of them, which should be reached during the simulated time or at
a final endpoint by an optimal treatment procedure. We also include penalty terms for cytotoxic
and antingiogenic effects, which could be ultimately linked to the corresponding drug concentrations
following the usual linear paradigm in the literature [6, 8, 14, 16, 25, 34, 46, 50, 77]. From the
mathematical viewpoint we prove that the functional reaches its minimum at the optimal values of
the cytotoxic and antiangiogenic effects, that is, it provides the optimal design of the treatment which
may possibly lead to a final desired result regarding the decrease of the tumor and/or of the PSA.
The necessary conditions that should be satisfied by the optimal values are determined by means of
the adjoint problem.
In this work, we also propose an algorithm implementing the steepest-descent gradient method
to solve our optimal control problem [3], which relies on IGA [37] and the generalized-α method
[13, 44] to discretize the involved forward and adjoint problems in space and time, respectively. We
then use this algorithm in a simulation study to analyze the performance of our optimal control
problem. In general, we observed a remarkable agreement between our numerical approximations of
the optimal drug effects and the theoretical formulations found in Section 4. Our results show that
accounting for the spatio-temporal evolution of the tumor morphology in the objective functional
(i.e., J1 in Section 6) led to superior optimal drug effects, which precisely adapt the optimal therapy
to tumor dynamics and would lead to drug protocols with expected lower toxicity compared to the
optimal drug effects obtained by only accounting for the final tumor morphology or volume at t = T
(i.e., J2 and J3 in Section 6 respectively). A previous simulation study on our PCa model [16]
revealed that drug-induced changes in tumor morphology during chemotherapy may contribute to
chemoresistance, which supports the inclusion of spatio-temporal dynamics of tumor morphology in
the objective functional to refine the design of optimal drug therapies.
The simulated cases of our optimal control problem in Section 6 feature S(t) ≈ 0. We think
that these results might align with the studies suggesting that antiangiogenic therapy might not be
optimal, and hence that a cytotoxic monotherapy would suffice to optimally treat advanced PCa
[2, 48, 71, 74, 83, 85–87, 89]. However, several methodological shortcomings have been detected
in clinical studies of antiangiogenic therapies, requiring a closer monitoring of pathological events
to account for a more direct control of tumor evolution than survival endpoints and serum PSA
[2, 71, 83, 85]. Some of these monitoring variables are already considered or could be added to the
objective functional in our optimal control framework. Furthermore, we plan to study the selection
of the values of the weighting constants ki, i = 1, . . . , 7, in the objective functional J to define a
constant set enabling the consistent design of personalized optimal drug protocols. We believe that
such a selection requires to account for the intrinsic scales in our PCa growth model. Consequently,
this update may result in optimal solutions with relevant antiangiogenic effects (e.g., Appendix B
shows some simulations with non-zero optimal S(t) for 0 < k7  1).
Additionally, our PCa model only includes antiangiogenic effects as a decrease in nutrient supply.
We plan to overcome this simplifying limitation by extending our model to account for the dynamics of
the evolving tumor-supporting vascular network [32]. This feature would enable a superior description
of nutrient and drug supply to the tumor and provide a clear target for antiangiogenic therapy
[6, 29, 30, 34, 50, 51, 77]. Accounting for the vascular network would also enable the study of the
synergistic or antagonistic effect of combining cytotoxic and antiangiogenic therapies, e.g., whether
the reduction of tumor microvasculature caused by antiangiogenic therapy may hamper the effective
delivery of cytotoxic drugs to the tumor or whether normalizing the tumor microvasculature would
effectively improve the supply of cytotoxic drugs [42, 69]. The dynamics of the tumor-induced
vascular network can be modeled following different approaches [93]. Hybrid models can capture
30
the evolving morphology of tumor-induced microvasculature with great detail, but usually require
intensive computational resources [23, 51, 54, 75, 91, 99]. Conversely, the local density of the
vascular network can be modeled using a continuous formulation [6, 30, 36, 50, 88, 93], which would
dramatically reduce the computational cost of simulations, especially at tissue and organ scale. This
advantage comes at the cost of losing geometrical precision, but it would still enable to account for
the tumor-induced vasculature observable in current magnetic resonance imaging [36, 98].
Our model of PCa growth could also be refined by incorporating the effect of tumor-induced
mechanical stresses on tumor dynamics, which has been shown to improve tumor forecasting [55, 97].
Indeed, a recent computational study suggests that the mechanical stresses created by PCa and
coexisting benign prostatic hyperplasia may obstruct tumor growth [59]. Accounting for tumor-
induced mechanical deformation can also improve the modeling of the tumor-supporting vascular
network [36, 81]. Furthermore, a poroelastic formulation would enrich the description of nutrient
and drug dynamics in the tumor region by taking into account how these phenomena are affected
by local changes in mechanical stress and fluid pressure [22, 43, 51]. This approach could provide
new insights on drug delivery and action in the complex tumor environment, enabling us to refine
therapeutic strategies accordingly. Our PCa growth model may also include multiphase formulations
accounting for several tumor species with varying responses to the prescribed therapy [24, 29, 41, 54,
79, 94]. To address the computational challenges of these model extensions and hence rationalize
the computational resource demand, our numerical methods could be accelerated by implementing
adaptive time stepping [26, 92], dynamic local adaptivity in the spatial discretization [11, 60], and
superior algorithms to solve the optimal control problem [3, 35].
Finally, we have also presented a strategy that decouples the problem of finding optimal treat-
ment solutions in two phases: first, we compute the optimal therapeutic effect in a drug-independent
optimal control framework, and, second, we calibrate alternative drug protocols for specific drug
dosage, effects, and pharmacodynamics targeting the calculated optimal therapeutic effect. The ap-
plication of this approach revealed interesting drug protocols that remarkably reproduced the desired
optimal effects simulated herein. We illustrate the design of a generic new drug in Section 7 by
employing the equivalent dose and effects of docetaxel because this is the most common compound
used for the chemotherapy of PCa, hence providing a reference for comparison during drug design.
However, our framework can also accommodate specific drug doses and effects, e.g., by respectively
choosing dc and calibrating βc with data in Eq. (7.1). The design of therapeutic solutions could be
further refined in multiple directions, e.g., by exploring alternative paradigms to model the dynamic
effects of specific cytotoxic and antiangiogenic drugs [28, 34, 39, 53, 73, 101], by explicitly includ-
ing drug toxicity (e.g., throughout the time integral of drug concentration [6, 53]), by accounting
for the synergistic action of drug combinations [39, 66], or by considering other forms of cancer
treatment (e.g., the cytotoxic action of radiation therapy [18, 33, 56, 77]). Ultimately, the optimal
pharmacodynamic properties calculated with our approach could assist in the development of new
drug compounds that are more efficacious, show lower toxicities, and may even target specific cancer
subtypes or patient-specific tumors [38, 40, 63, 84]. We also plan to explore the design of drug
protocols for 3D PCa growth scenarios and considering longer simulation times, which are closer to
the reality of experimental and clinical settings [16, 48, 59–61, 68]. Additionally, the acquisition
of longitudinal PSA and imaging data during treatment would enable to recalibrate key parameters
in our framework, for example: tumor proliferation and apoptosis in our PCa model, or drug effect
rates βc and βa during drug protocol design. Although we have assumed these parameters to be
constant, they are known to vary due to treatment action and the phenotypic evolution of the tumor
[24, 32, 39, 49, 83]. Data-driven reparameterization would also enable us to update the optimal con-
trols, adapt the design of personalized drug protocols accordingly, and early detect the emergence
of chemoresistance patterns. In sum, we believe that our optimal control framework can provide
a versatile and powerful approach to investigate patient-specific therapeutic strategies in silico to
succesfully treat advanced PCa.
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Appendix A. Supplementary mathematical results.
The notation we use in this appendix is somehow independent from the one in the paper. We are
going to check that if u, v are two measurable functions defined on Ω and F : R → R is a C1
function, then there exists a measurable function w : Ω→ R attaining intermediate values between
the ones of u and v and such that
F (u(x))− F (v(x)) = (u(x)− v(x))F ′(w(x)) a.e. x ∈ Ω. (A.1)
The whole argument is due to Vittorino Pata, with many thanks from the authors.
Theorem A.1. Let f : R → R be a continuous function. Then f has a Borel measurable right
inverse k defined on (the interval) Im(f).
For the proof of Theorem A.1 we need a lemma.
Lemma A.2. Let f : [a, b]→ R be continuous. Then the function k : f([a, b])→ [a, b] given by
k(t) = inf {y ∈ R; f(y) = t}
is Borel measurable. Besides, for every t ∈ f([a, b]), we have that
f(k(t)) = t.
Proof. The latter equality is obvious, since f is continuous, and so the infimum is actually a
minimum. Let us prove the first assertion. Let t be fixed, such that k(t) 6= a. We will show that k
is either left or right continuous at t. This is enough to ensure that k is Borel measurable. To this
end, call y = k(t) ∈ (a, b]. By definition, f(τ) 6= y whenever τ < t. Assume then that f(τ) < y for
all τ < t. We prove that k is left continuous at y (if instead f(τ) > y for all τ < t then k is right
continuous at y, the proof being the same). By contradiction, if k is not left continuous, there is
yn ↑ y such that tn = k(yn) 6→ k(y) = t. By compactness, there is t¯ < t such that tn → t¯, up to a
subsequence. But since f is continuous, yn = f(tn)→ f(t¯), so that f(t¯) = y. This contradicts the
fact that t is the smallest element of [a, b] for which the equality f(t) = y holds. 
Proof of Theorem A.1. For every n ∈ Z, let
A′n = f([n, n+ 1)).
We now modify the sets A′n in order to have them disjoint. Hence we put
A0 = A
′
0, A1 = A
′
1 \A0, A−1 = A′−1 \ (A0 ∪A1), A2 = A′2 \ (A0 ∪A1 ∪A−1),
and so on. Possibly, some An can be empty, and we simply ignore it. Clearly, we have⋃
nAn = Im(f).
Let now fn be the restriction of f on [n, n+ 1], and let kn : f([n, n+ 1])→ [n, n+ 1] be given by
kn(t) = inf{f−1n (t)},
From the Lemma, kn is Borel measurable and fn(kn(t)) = t for all t ∈ f([n, n+ 1]). Finally, define
the (Borel measurable) function
k(t) = kn(t), t ∈ An.
Then, for t ∈ An, we have that f(k(t)) = fn(kn(t)) = t. 
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Remark A.3. With inessential changes in the proof, Theorem A.1 still holds if f is defined on a
generic interval I.
Corollary A.4. Given a domain Ω ⊂ Rn, let µ : Ω→ R be a measurable function (finite everywhere),
and let f : R → R be a continuous function such that Im(f) ⊃ Im(µ). Then there exists a
measurable function q : Ω→ R such that
f(q(x)) = µ(x), for all x ∈ Ω.
Proof. By Theorem A.1, let k be the Borel measurable right inverse of f , and define
q(x) = k(µ(x)), x ∈ Ω.
q is Lebesgue measurable, being the composition of a Borel measurable function and a Lebesgue
measurable one. 
We finally conclude with the desired application involving the Lagrange mean value theorem.
Corollary A.5. Given a domain Ω ⊂ Rn, n ∈ N, let u, v : Ω → R be measurable functions
(finite everywhere), and let F : R → R be a C1 function. Then there exists a measurable function
w : Ω→ R such that (A.1) holds. 
Proof. We define
µ(x) =

F (u(x))− F (v(x))
u(x)− v(x) if u(x) 6= v(x),
F ′(u(x)) if u(x) = v(x).
Then the problem amounts to finding a measurable function w such that
F ′(w(x)) = µ(x), x ∈ Ω.
The Lagrange theorem implies that Im(F ′) ⊇ Im(µ). Hence, the conclusion follows from Corol-
lary A.4 by taking w = q. 
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Appendix B. Supplementary simulations.
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Figure B.1: Results of the optimal control problem using functional J1 with k1 = k2 = k4 = 1, k6 = 1, and
k7 = 1, 10
−1, 10−2, 10−3. (A) Optimal cytotoxic effects U(t) obtained for each value of k7 compared to standard
docetaxel therapy (U0(t), gray dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45)
(overlapping white dashed lines). (B) Optimal antiangiogenic effects S(t) obtained for each value of k7 compared to
standard bevacizumab therapy (S0(t), gray dotted line) and the corresponding theoretical estimates calculated with
Eq. (4.45) (overlapping white dashed lines). (C) Evolution of tumor volume vφ (left) and serum PSA Ps (right) using
the optimal U(t) and S(t) obtained via simulation for each value of k7 compared to standard combined therapy, i.e.,
vφ,0 and Ps,0 respectively (gray dotted lines).
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Figure B.2: Results of the optimal control problem using functional J2 for k2 = k4 = 10, k6 = 1, and k7 =
1, 10−1, 10−2, 10−3. (A) Optimal cytotoxic effects U(t) obtained for each value of k7 compared to standard docetaxel
therapy (U0(t), gray dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45) (overlapping
white dashed lines). (B) Optimal antiangiogenic effects S(t) obtained for each value of k7 compared to standard
bevacizumab therapy (S0(t), gray dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45)
(overlapping white dashed lines). (C) Evolution of tumor volume vφ (left) and serum PSA Ps (right) using the optimal
U(t) and S(t) obtained via simulation for each value of k7 compared to standard combined therapy, i.e., vφ,0 and Ps,0
respectively (gray dotted lines).
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Figure B.3: Results of the optimal control problem using functional J3 for k3 = k4 = 5, k6 = 1, and k7 =
1, 10−1, 10−2, 10−3. (A) Optimal cytotoxic effects U(t) obtained for each value of k7 compared to standard docetaxel
therapy (U0(t), gray dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45) (overlapping
white dashed lines). (B) Optimal antiangiogenic effects S(t) obtained for each value of k7 compared to standard
bevacizumab therapy (S0(t), gray dotted line) and the corresponding theoretical estimates calculated with Eq. (4.45)
(overlapping white dashed lines). (C) Evolution of tumor volume vφ (left) and serum PSA Ps (right) using the optimal
U(t) and S(t) obtained via simulation for each value of k7 compared to standard combined therapy, i.e., vφ,0 and Ps,0
respectively (gray dotted lines).
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